Table 5.
Comparison group 1 vs. group 2. The rhGH treatment: GV, BMI SDS, HOMA-IR, time of adrenarche and central puberty (the mean value ± standard deviation score, SDS).
| Group | Height SD rhGH Start, p = 0.15 |
Height SD GH1 | Height SD GH2 | GV GH1 | GV GH2 | BMI SDS rhGH Start, p < 0.05 |
BMI SDS GH1 | BMI SDS GH2 | HOMA-IR |
|---|---|---|---|---|---|---|---|---|---|
| 1 | −1.7 ± 1.3 | −1.1 ± 1.2 | −0.6 ± 1.8 | 9.0 ± 1.8 | 6.1 ± 2.0 | 0.8 ± 1.2 | −0.6 ± 1.1 | 0.6 ± 1.1 | 2.5 ± 1.4 |
| 2 | −2.5 ± 1.4 | −1.3 ± 1.1 | −1.2 ± 0.9 | 9.6 ± 2.0 | 5.9 ± 1.0 | 1.8 ± 1.5 | −0.1 ± 1.2 | 1.1 ± 1.3 | 3.0 ± 2.0 |
RhGH: recombinant human growth hormone, GV: growth velocity, GH1: the mean time of rhGH treatment of 1.4 and 1.2 years (groups 1 and 2), GH2: the mean time of rhGH treatment of 6.0 years (groups 1 and 2), BMI: body mass index, HOMA-IR: homeostasis model assessment of insulin resistance.